Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214879 | 0.98 | KDM4E (0.41) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL27346203 | 0.91 | KDM4E (0.40) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL824152 | 0.91 | SMN1; SMN2 (0.45) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL15292513 | 0.85 | CYP3A4 (0.36) | KDM4ECYP2D6 | |
| SCHEMBL1615683 | 0.85 | CYP3A4 (0.36) | KDM4ECYP2D6 | |
| SCHEMBL13542421 | 0.85 | CYP3A4 (0.36) | KDM4ECYP2D6 | |
| SCHEMBL23965559 | 0.83 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2HSD11B1CYP2D6KMT2A | |
| SCHEMBL14519150 | 0.83 | DRD2 (0.41) | SMN1; SMN2 | |
| SCHEMBL22737188 | 0.81 | SMN1; SMN2 (0.38) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL14519151 | 0.80 | KMT2A (0.39) | KDM4ESMN1; SMN2OPRM1OPRL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283263-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| WO-2018119362-A2 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICALS INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | KDM4E 4083/4885SMN1; SMN2 2797/4885HSD11B1 1/4885 |
| US-10012650-B2 | Assays for BTK inhibitors | BTK, SYK, LYN | KDM4E 692/4885SMN1; SMN2 4495/4885HSD11B1 3499/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | KDM4E 3296/4885SMN1; SMN2 3654/4885HSD11B1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.